Coils for Treating Brain Aneurysm

Called Matrix2, the 360o coils have been cleared by the U.S. Food and Drug Administration (FDA).

The Matrix2 coils feature a complex shape designed to allow greater conformability and more uniform distribution within intracranial aneurysms. The design includes 1.5 loops at the beginning of the coil that are 25% smaller than the overall coil diameter. This multi-diameter design is intended to offer more precise, controlled delivery and facilitate first-time placement. The smooth biopolymer coil surface decreases coil-on-coil friction by 35% over earlier models.

Many brain aneurysm patients are treated by neurosurgical clipping, a surgical procedure that involves temporarily removing a section of the skull. However, patients are increasingly having less-invasive treatments using endovascular coil embolization, in which tiny platinum coils are threaded through the vascular system and deployed in the aneurysm, blocking blood flow into the aneurysm and preventing rupture.

"The Matrix2 360o coils complement our existing Matrix Coils portfolio and offer our latest advancements in coil embolization,” said Milton McColl, president, neurovascular business, Boston Scientific Corporation (Natick, MA, USA), which developed the Matrix2 coils. "The new shape of the coils is designed to offer greater conformability and more efficient packing to facilitate treatment across a wider variety of intracranial aneurysms.”

Conventional neurosurgical clipping often requires a long hospital stay and can be associated with higher complication rates, according to Boston Scientific. Less-invasive endovascular coil treatment has been associated with lower risk of negative outcomes, shorter hospital stays, and shorter recovery times, compared to surgery.




Related Links:
Boston Scientific